{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:30:55Z","timestamp":1792603855761,"version":"4.5.0"},"posted":{"date-parts":[[2025,12,29]]},"group-title":"Genetic and Genomic Medicine","reference-count":15,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine alterations in circulating Tau and phosphorylated Tau (pTau) profiles in pediatric and adult patients with spinal muscular atrophy (SMA).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Circulating total Tau, pTau-181, pTau-217, pTau-262, and pTau-396 concentrations were measured across three cohorts: 1) adults including healthy controls, SMA patients, and ALS patients; 2) pediatric SMA patients and age-matched controls; and 3) pediatric SMA patients treated with onasemnogene abeparvovec.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Distinct alterations in circulating Tau species were detected in adult SMA and ALS. Among all measurements, pTau-262 emerged as the only species specifically elevated in adult SMA, while total Tau levels were comparable between adult SMA and controls but significantly increased in ALS. Tau alterations were not consistently observed in pediatric SMA, although a small subset showed elevated levels, underscoring the value of individualized biomarker monitoring upon diagnosis. In gene-therapy\u2013treated infants, Tau levels increased transiently several weeks after onasemnogene abeparvovec injection, paralleling previously described neurofilament kinetics and suggesting acute, treatment-associated neuronal stress.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Circulating Tau, particularly pTau-262, may serve as a disease-relevant biomarker in adult SMA, while pediatric profiles appear more heterogeneous. Transient Tau elevations after gene therapy may reflect acute neuronal vulnerability and warrant further investigation.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2025.12.19.25342711","type":"posted-content","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:05:13Z","timestamp":1767009913000},"source":"Crossref","is-referenced-by-count":1,"title":["Circulating Tau Profiles in Pediatric and Adult Patients with Spinal Muscular Atrophy"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-660X","authenticated-orcid":false,"given":"Leillani L.","family":"Ha","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunayana","family":"Mitra","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Fillingham","sequence":"additional","affiliation":[{"name":"Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Berry","sequence":"additional","affiliation":[{"name":"Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Swoboda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Department of Neurology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiano R. R.","family":"Alves","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Department of Neurology, Harvard Medical School, Boston, MA, USA"},{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025123108200893000_2025.12.19.25342711v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2019.07.004"},{"key":"2025123108200893000_2025.12.19.25342711v1.2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbadis.2004.06.017","article-title":"Tau phosphorylation: physiological and pathological consequences","volume":"1739","year":"2005","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"2025123108200893000_2025.12.19.25342711v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1707-9"},{"key":"2025123108200893000_2025.12.19.25342711v1.4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JHD-230588","article-title":"Age-Dependent Increase in Tau Phosphorylation at Serine 396 in Huntington\u2019s Disease Prefrontal Cortex","volume":"12","year":"2023","journal-title":"JHD"},{"key":"2025123108200893000_2025.12.19.25342711v1.5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.598907"},{"key":"2025123108200893000_2025.12.19.25342711v1.6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26462"},{"key":"2025123108200893000_2025.12.19.25342711v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlz041"},{"key":"2025123108200893000_2025.12.19.25342711v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57144-7"},{"key":"2025123108200893000_2025.12.19.25342711v1.9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamaneurol.2013.6064","article-title":"Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis","volume":"71","year":"2014","journal-title":"JAMA Neurol"},{"key":"2025123108200893000_2025.12.19.25342711v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06916-4"},{"key":"2025123108200893000_2025.12.19.25342711v1.11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3109\/17482968.2011.622405","article-title":"Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment","volume":"13","year":"2012","journal-title":"Amyotrophic Lateral Sclerosis"},{"key":"2025123108200893000_2025.12.19.25342711v1.12","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3716-14.2015"},{"key":"2025123108200893000_2025.12.19.25342711v1.13","first-page":"e921","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","year":"2020","journal-title":"Neurology"},{"key":"2025123108200893000_2025.12.19.25342711v1.14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series","volume":"23","year":"2021","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"2025123108200893000_2025.12.19.25342711v1.15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JND-230054","article-title":"Identifying Biomarkers of Spinal Muscular Atrophy for Further Development","volume":"10","year":"2023","journal-title":"J Neuromuscul Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2025.12.19.25342711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:20:20Z","timestamp":1767198020000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2025.12.19.25342711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.64898\/2025.12.19.25342711","relation":{},"subject":[],"published":{"date-parts":[[2025,12,29]]},"subtype":"preprint"}}